Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed care populations across Los Angeles and Orange counties, will provide coverage for the company’s Epi+Gen CHD and PrecisionCHD tests for eligible members with prior authorization. The coverage expands access to physician-ordered blood tests designed to assess coronary heart disease risk and support diagnosis and personalized treatment planning.
The company noted that Epi+Gen CHD evaluates a patient’s three-year risk of a coronary heart disease event, while PrecisionCHD helps diagnose coronary heart disease and identify its underlying molecular drivers. Both tests are noninvasive blood-based diagnostics that do not require fasting or radiation exposure, supporting broader adoption of precision cardiovascular medicine across community healthcare networks. This development is significant because it brings advanced, AI-driven diagnostic tools to a wider patient population within managed care settings, potentially improving early detection and management of cardiovascular disease, a leading cause of death globally.
Atlas Healthcare Physicians serves a diverse patient base in a highly populated region of California, and the inclusion of these tests in their coverage portfolio could set a precedent for other independent physician associations and insurance networks. For patients, this means access to cutting-edge, noninvasive testing that can provide personalized risk assessment and guide treatment decisions without the need for more invasive procedures or radiation exposure. For the healthcare system, earlier and more precise diagnosis can lead to better outcomes and potentially reduce long-term costs associated with advanced cardiovascular disease.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. This partnership with Atlas Healthcare Physicians represents a strategic step toward integrating precision medicine into routine clinical practice, particularly in community healthcare networks.
The implications for the industry are substantial. As more healthcare providers adopt AI-based diagnostics, the standard of care for cardiovascular disease could shift from reactive treatment to proactive, personalized prevention. This move also highlights the growing trend of value-based care, where payers and providers seek cost-effective interventions that improve patient outcomes. By securing coverage for these tests, Cardio Diagnostics is validating the clinical utility and economic value of its technology, which could encourage further adoption by other healthcare organizations.
For more information about Cardio Diagnostics, visit the company’s newsroom at https://nnw.fm/CDIO. The full press release is available at https://nnw.fm/EFQen.
